Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial

The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。